Guillain-Barré syndrome

被引：0

作者：

Urban P.P. ^{[1
]}

Nix W.A. ^{[1
]}

机构：

[1] Klinik und Poliklinik für Neurologie, Johannes Gutenberg Universität Mainz, 55101 Mainz

来源：

Notfall & Rettungsmedizin | 2005年 / 8卷 / 4期

关键词：

Guillain-Barré-Syndrom; Immunoglobulins; Miller-Fisher-syndrome; Plasmapheresis;

D O I：

10.1007/s10049-005-0739-1

中图分类号：

学科分类号：

摘要：

The Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyneuropathy with progressive flaccid limb weakness which evolves more or less symmetrically over a period of several days also affecting the sensory nerves in most cases. Frequently, the cranial nerves, the respiratory muscles, and the autonomic system are also affected. Most often, GBS occurs after a preceding bacterial or viral illness and the immune-mediated demyelination preferentially affects the nerve roots and distal nerve terminals. Equal effective and causal treatment options are plasmapheresis and high-dose immunoglobulins. Steroids show no benefit. The prognosis is also improved by an effective symptomatic treatment including mechanical ventilation or treatment of the autonomic dysfunction. © Springer Medizin Verlag 2005.

引用

页码：281 / 285

页数：4

共 20 条

[1]

Buchwald B., Toyka K.V., Zielasek J., Weishaupt A., Schweiger S., Dudel J., Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: A macro-patch-clamp study, Ann. Neurol., 44, pp. 913-922, (1998)

[2]

Flachenecker P., Toyka K.V., Reiners K., Herzrhythmusstörungen beim Guillain-Barré-Syndrom. Eine Übersicht zur Diagnostik einer seltenen, aber potenziell lebensbedrohlichen Komplikation, Nervenarzt, 72, pp. 610-617, (2001)

[3]

Govoni V., Granieri E., Epidemiology of the Guillain-Barré syndrome, Curr. Opin. Neurol., 14, pp. 605-613, (2001)

[4]

Green D.M., Ropper A.H., Mild Guillain-Barré syndrome, Arch. Neurol., 58, pp. 1098-1101, (2001)

[5]

Guillain G., Barre J.A., Strohl A., Sur un syndrome de radiculo-névite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: Remarques sur les caractères cliniques et graphiques des réflexes tendineux, Bull. Coc. Méd. Hôp. Paris, 40, pp. 1462-1470, (1916)

[6]

Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome, Lancet, 341, pp. 586-590, (1993)

[7]

Hartung H.P., Willison H.J., Kieseier B.C., Acute immunoinflammatory neuropathy: Update on Guillain-Barré syndrome, Curr. Opin. Neurol., 15, pp. 571-577, (2002)

[8]

Hughes R.A., van der Meche F.G., Corticosteroids for Guillain-Barré syndrome, Cochrane Database Syst. Rev., 3, (2003)

[9]

Hughes R.A.C., Raphael J.C., Swan A.V., van Doorn P.A., Intravenous immunoglobulin for Guillain-Barré syndrome, Cochrane Database Syst. Rev., 1, (2004)

[10]

Koningsveld van R., Schmitz P.I.M., van der Meche F.G.A., Visser L.H., Meulstee J., van Doorn P.A., Effect of methylpredisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: Randomised trial, Lancet, 363, pp. 192-196, (2004)

← 1 2 →